
Intercept Pharmaceuticals (NASDAQ:ICPT) brought in sales totaling $92.40 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 898.9%, resulting in a loss of $36.28 million. Intercept Pharmaceuticals collected $92.83 million in revenue during Q3, but reported earnings showed a $3.63 million loss.